NEW YORK and SYDNEY, Australia, August 18, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer…
NEW YORK and SYDNEY, Australia, May 28, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announced that it has signed a Memorandum of…
NEW YORK and SYDNEY, April 27, 2021, Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announced that it has received the notification that its SARS-CoV-2 Antigen Test…
From January 29 to February 4, President of Beroni USA Mr. Linfeng Li came to Guang Zhou with “Virus Hunter” Professor Walter Ian Lipkin, helping prevent and control COVID-19 outbreak.…
On December 21, 2020, Australia, Beroni Group Limited (“Beroni Group”) announces it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its newly developed…
NEW YORK and SYDNEY, November 10, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development,…
NEW YORK and SYDNEY, November 9, 2020 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise announced today that the Company has been…
NEW YORK and SYDNEY, October 19, 2020, Beroni Group (“Beroni”) announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (“GenScript”), a leading global biotechnology company.…
